LEARNING OBJECTIVES:

- Outline the pathogenesis, diagnosis and treatment of inflammatory bowel diseases.
- Differentiate ulcerative colitis from Crohn disease.
- Differentiate irritable bowel syndrome (IBS) from other common gastrointestinal disorders.
- Identify strategies for the management of IBS.
- Differentiate complicated versus uncomplicated diverticulitis.
- Compare treatment options available for the management of diverticulitis.
- Identify barriers to colorectal cancer screening and utilize appropriate strategies to promote screening.
- Identify the novel strategies and clinical guidelines for the management of inflammatory bowel disease (IBD).
- Outline the diagnosis and treatment strategies for patients with IBD that are difficult to treat.
- Evaluate the efficacy and safety of current and emerging therapeutic strategies for the treatment of hepatitis C virus (HCV).
- Discuss the role of gut microbiota in GI health and disease.
- Identify strategies for the management of IBD-related cardiac and vascular disorders.
- Identify the new strategies and clinical guidelines for the management of inflammatory bowel disease (IBD).
- Implement and endoscopic ultrasound treatment strategies for patients with digestive diseases and recognize the role of new technologies and technology to improve and expand available therapeutic options.
- Discuss the emerging paradigm for diagnosis and management of acute pancreatitis.
- Discuss the role of portosystemic shunts in the management of cirrhotic cardiomyopathy.
- Assess current concepts in the management of hepatic cancer.
- Discuss current and emerging therapeutic strategies for the treatment of alcoholic hepatitis.
- Assess current standards of care for the management of alcoholic hepatitis.
- Summarize the novel strategies to expand the availability of donor livers.
- Summarize the novel strategies to expand the availability of donor livers.
- Discuss the emerging paradigm in the management of hepatitis C virus.
- Evaluate the role of new therapies in the management of viral hepatitis.
- Describe current and emerging strategies for managing patients with nonalcoholic steatohepatitis.
- Summarize the novel strategies to expand the availability of donor livers.

Join us in March at the 5th Annual Digestive Diseases: New Advances

The complexity and magnitude of medical advances in the management of digestive diseases make it ever more challenging for clinicians to apply this tremendous amount of information to their practice. This activity will provide learners with a comprehensive overview of the state-of-the-art advances in the diagnostic, therapeutic, and preventive modalities of digestive diseases based on the latest evidence, literature, and clinical research. A thorough review of the current treatment landscape is vital to both clinicians and patients who can benefit from the expansion of therapeutic options.

We look forward to seeing you in Philadelphia from March 16-17, 2018. Don’t miss out! Register today and save up to $170 with our early discount which ends February 28, 2018.

Program Chair

Nikolaos Pyrsopoulos, MD, PHD, MBA, FACCP, AGAF, FJASLD

Chief of Gastroenterology and Hepatology

Rutgers New Jersey Medical School

Medical Director, Liver Transplantation

University Hospital, Newark, NJ

WHO SHOULD ATTEND:

This conference is designed for gastroenterologists, primary care physicians, advanced practice nurses, nurses, pharmacists, and physician assistants involved in the diagnosis, evaluation, management, and treatment of patients with digestive diseases.

ABSTRACT SUBMISSIONS:

Authors are invited to submit abstracts to be considered for posters at the 5th Annual Digestive Diseases: New Advances. Posters can only be submitted by registered attendees. Please contact Steven Krawitz, MD, Rutgers New Jersey Medical School, at sak290@njms.rutgers.edu for more information and to submit your poster.
## CONFERENCE AGENDA

**THURSDAY, MARCH 15, 2018**

**3:00 PM – 5:30 PM** Registration. Pack up Badges.  

**FRIDAY, MARCH 16, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 AM</td>
<td>Registration, Continental Breakfast, Visit Exhibits/Posters</td>
</tr>
<tr>
<td>7:55 AM</td>
<td>Welcome Back</td>
</tr>
</tbody>
</table>

**UPPER GI SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Welcome Back</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>Interactive Panel Discussion</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Welcome Back</td>
</tr>
</tbody>
</table>

**LIVER SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>Welcome Back</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Interactive Panel Discussion</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Welcome Back</td>
</tr>
</tbody>
</table>

**UPPER GI SESSION II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 AM</td>
<td>The Risk and Benefits of Proton Pump Inhibitors</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Visit Exhibits/Posters</td>
</tr>
</tbody>
</table>

**UPPER GI SESSION III**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:55 PM</td>
<td>Bundled Payment Programs</td>
</tr>
</tbody>
</table>

**SIDDHART VERMA, DO, JD**

Moderator: David C. Metz, MD

**IBD/IBS SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 PM</td>
<td>Colorectal Cancer Screening: Are We Missing Something?</td>
</tr>
</tbody>
</table>

**KEYNOTE SPEAKER**

Brian L. Strom, MD, MPH  

Executive Vice President for Health Affairs  

Hepatitis B and C  

Rutgers, The State University of New Jersey

**FACULTY**

Charles A. Horsky, MD, FACP  

Associate Professor of Medicine  

Division of Hepatology  

Rutgers New Jersey Medical School

Peter H.R. Green, MD  

Professor of Medicine  

Department of Medicine  

Columbia University College of Physicians

**PROGRAM CHAIR**

Nabargument Y. Kim, MD, PhD, MBA, FACP, AGAF, FASID  

Professor of Medicine  

Chief of Gastroenterology  

Rutgers New Jersey Medical School

**HOTEL INFORMATION**

The Westin Philadelphia  

99 South 17th Street  

Philadelphia, PA 19103  

Phone: 215-375-9600  

**Hotel Reservations**

For hotel reservations by phone call 1-800-WESTIN-1  

For online hotel reservations: https://rutgers.eventmobi.com/  

**Method of Participation**

In order to meet the learning objectives and receive continuing medical education credits, participants are expected to check in at the registration desk both days, attend the program and complete an online evaluation form at the conclusion of the program. A letter certifying attendance and credit verification will be emailed to participants upon completion of the online evaluation survey.

**CMCE ACCREDITATION**

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Global Academy for Medical Education. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Academy of Pysicians (AAP), to provide continuing education for the healthcare team.

**PHYSICIANS**

Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 31 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**PHARMACISTS**

This knowledge-based activity satisfies for 13 contact hours (1.30 CEUs) of continuing pharmacy education credit. Universal Activity Number 37096999-18-001-01P-EF Rho 07/05/2017 18-001-01P-EF 07/05/2018.

Your NAPF Pro ID number is required to submit the completion of the program. CPE credit will be processed after the program evaluation has closed and participants, which will be three to five weeks following the activity date.

**NURSES**

This activity awarded 13 contact hours. 80 minutes IoT Nurses should only claim those contact hours actually spent participating in the activity.

**PHYSICIAN ASSISTANTS**

A P.A. must verify participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. We may receive a maximum of 13 Category 1 credits for completing this activity.

**CME NOC**

Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**FACULTY DISCLOSURE**

All individuals who offer content of continuing education activities are required to disclose to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose all affiliations and/ or investigational uses in their presentations. These disclosures will be made to the audience at the time of the activity.